IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The fim develops drugs for Parkinson's disease. It also offers IRL752 that targets dementia in Parkinson's disease. The company was founded in 2013 and is headquartered in Gothenburg, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company